RxDoctor Payments DataLook up a doctor →

Komal Ashraf, DO

Epilepsy · Columbia, MONPI 1457580490

Payments from drug & device makers

$225,408in general payments, 2019–2025

Across 783 payments — averaging $287.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$91K
  • SK Life Science, Inc.$59K
  • AbbVie$55K
  • Livanova USA, Inc.$13K
  • Jazz Pharmaceuticals Inc.$2K
  • Greenwich Biosciences, Inc.$1K
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$11,2106%
  • Speaking & faculty fees$164,56581%
  • Travel & lodging$10,1075%
  • Food & beverage$16,4728%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,408 in reported general payments places this provider in the 85th percentile of 26 epilepsy providers in Missouri.

See all epilepsy providers in Missouri

Medicare billing

Part B allowed, 2024
$54,083
Medicare patients
222
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam245$468,267
FinteplaFenfluramine Hcl18$313,382
EpidiolexCannabidiol (Cbd)64$253,253
AptiomEslicarbazepine Acetate118$190,719
XcopriCenobamate132$172,321
NuedextaDextromethorphan Hbr/Quinidine41$71,791
UbrelvyUbrogepant55$68,155
NayzilamMidazolam47$40,292
Emgality PenGalcanezumab-Gnlm50$35,231
Lacosamide232$33,890
ValtocoDiazepam22$23,346
Nurtec OdtRimegepant Sulfate15$22,813
QuliptaAtogepant11$18,913
Carbamazepine ErCarbamazepine37$4,066
Levetiracetam95$3,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Fintepla, Nayzilam$91,118$821,940310 claims
Sunovion Pharmaceuticals Inc.Aptiom$19$190,719118 claims
SK Life Science, Inc.Xcopri$58,647$172,321132 claims
AbbVieUbrelvy, Qulipta$55,289$87,06866 claims
Avanir Pharmaceuticals, Inc.Nuedexta$191$71,79141 claims
Neurelis, Inc.Valtoco$96$23,34622 claims
PfizerNurtec Odt$115$22,81315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 26 epilepsy providers in Missouri.

Other epilepsy in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →